

Date: January 9, 2024

To: Iowa Vaccines for Children (VFC) Program Providers

From: Iowa VFC Program

Re: Vaccine Update - Maternal RSV Vaccine

Effective January 9, 2024, the Iowa VFC Program will allow providers to begin ordering Pfizer's RSV vaccine, Abrysvo.

Abrysvo is the only vaccine indicated for use in pregnant persons to protect infants from RSV-associated lower respiratory tract infection. Abrysvo should be administered during 32 through 36 weeks gestation (i.e., 32 weeks 0 days through 36 weeks 6 days), and from September through January.

A detailed Maternal RSV vaccine summary is available on the <u>VFC Program Website</u> and includes information on use, dosage, schedule, and contraindications.

## **VFC Program Inventory and Ordering**

Maternal RSV vaccine is considered a non-routine vaccine for most VFC providers based on the populations they serve. As a non-routine vaccine for most VFC providers, providers are not required to stock RSV maternal vaccine as part of their routine inventory.

Due to limited availability and specific eligible-population, VFC Providers will need to request maternal RSV doses in IRIS in the "Special Comments for Order" box, such as:

Special Comments for Order	
Enter Text: 91 characters left.	
requesting 1 RSV maternal vaccine dose for pregnant patient	
	1

This process is the same as requesting the PPSV23 vaccine for specific eligible-populations.

VFC providers should continue to place routine vaccine orders consistent with their economic order quantity (monthly, bimonthly or quarterly) and monitor existing inventory to ensure VFC vaccine is not wasted or allowed to expire. Vaccine wastage and unnecessary vaccine expiration may result in restitution per the Vaccine Restitution Policy.

For questions, contact the Iowa VFC Program at IowaVFC@hhs.iowa.gov.